TY - JOUR
T1 - A multicenter phase II trial of 4′-Iodo-4′-deoxydoxorubicin (IDOX) in primary amyloidosis (AL)
AU - Gertz, Morie A.
AU - Lacy, Martha Q.
AU - Dispenzieri, Angela
AU - Cheson, Bruce D.
AU - Barlogie, Bart
AU - Kyle, Robert A.
AU - Palladini, Giovanni
AU - Geyer, Susan M.
AU - Merlini, Giampaolo
PY - 2002
Y1 - 2002
N2 - Introduction. 4′-Iodo-4′-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results. Methods. Patients with biopsy-proven amyloidosis were required to have a cardiac ejection fraction > 50%, ventricular septal thickness <20 mm, serum creatinine <2.5 mg per dL, bilirubin ≤ 2.0 mg per dL, neutrophils <1,500 per μL, and platelets > 100,000 per μL. IDOX was administered intravenously over 1 hour at a dose of 15 mg per m2 once a week for 4 consecutive weeks. This therapy was repeated every 3 months up to 4 times. Results. Twenty-five previously treated and 15 untreated patients with primary amyloidosis (AL) received therapy. Fifteen patients had > 3 g of protein per day in the urine. Eleven patients had an ejection fraction <60%. One, 2, 3, 4, and 5 organ systems were involved in 22, 10, 4, 3, and 1 patient, respectively. The median time between diagnosis and initiation of IDOX was 17.4 months. There were 6 responses (15%). Twelve of the patients have died. Conclusion. IDOX administered in this protocol was insufficiently active at the current dose.
AB - Introduction. 4′-Iodo-4′-deoxydoxorubicin (IDOX) has been reported to bind to and lead to the catabolism of amyloid deposits. A multicenter study attempted to develop a dosing schedule to confirm those results. Methods. Patients with biopsy-proven amyloidosis were required to have a cardiac ejection fraction > 50%, ventricular septal thickness <20 mm, serum creatinine <2.5 mg per dL, bilirubin ≤ 2.0 mg per dL, neutrophils <1,500 per μL, and platelets > 100,000 per μL. IDOX was administered intravenously over 1 hour at a dose of 15 mg per m2 once a week for 4 consecutive weeks. This therapy was repeated every 3 months up to 4 times. Results. Twenty-five previously treated and 15 untreated patients with primary amyloidosis (AL) received therapy. Fifteen patients had > 3 g of protein per day in the urine. Eleven patients had an ejection fraction <60%. One, 2, 3, 4, and 5 organ systems were involved in 22, 10, 4, 3, and 1 patient, respectively. The median time between diagnosis and initiation of IDOX was 17.4 months. There were 6 responses (15%). Twelve of the patients have died. Conclusion. IDOX administered in this protocol was insufficiently active at the current dose.
KW - Amyloid
KW - Amyloidosis
KW - Anthracycline
KW - Cardiomyopathy
KW - Chemotherapy
KW - Nephrotic syndrome
UR - http://www.scopus.com/inward/record.url?scp=0036130774&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0036130774&partnerID=8YFLogxK
M3 - Article
C2 - 12000194
AN - SCOPUS:0036130774
VL - 9
SP - 24
EP - 30
JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
SN - 1350-6129
IS - 1
ER -